PARIS Applighne Oncor has published results for the first half of 1998 which show a 9.2 percent increase in revenues to FFr21.8 million and a net loss of FFr6.1 million, down slightly from FFr6.9 million in the first half of 1997.

Strasbourg-based Applighne, a supplier of biological substances and equipment to organizations researching the human genome, pointed out that particularly strong sales growth in the U.K. enabled it to offset the 30 percent drop in sales of instruments. The strategic shift from that business to higher-margin reagents, together with the development of the company¿s trading activities and the renegotiation of some purchase prices, resulted in a 66 percent jump in gross profit to FFr6.4 million.